Views & Analysis | Perspectives on pharma industry issues

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Articles

Pharma social media scan: the digital KOL – and all the othe...

In the latest in her series reviewing social media within pharma, Emma D’Arcy approaches the controversial notion of the digital KOL. By the time you read this (a phrase I’ve always wanted to utter – alongside “stop the press” and “follow that car”) I’ll be deep into a debate about new types of KOLs and the...

Articles

UK Bribery Act

In the third part of her series Jean Samuel offers advice on how to ensure that we are all adhering to the UK Bribery Act. On 1st July 2011 the UK Bribery Act comes into force. It addresses anti-bribery and corruption (ABC) and is tough in both its geographic and…

Articles

Qualifying the market in an online world

With so many ways to virtually connect, does offline research still have a place in pharma? Vishal Jhanjee talks to pharmaphorum about the future for online qualitative studies. As an industry, pharma has always placed a heavy emphasis on the power of market research studies to help it understand the market place...

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology